Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
22 nov. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
21 nov. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
14 nov. 2024 16h15 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
06 nov. 2024 07h30 HE
|
Plus Therapeutics Inc.; Spectron RX
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
05 nov. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
29 oct. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
01 oct. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
18 sept. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 sept. 2024 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
14 août 2024 16h16 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights